

Table 1: *H. pylori* prevalence in IBD patients vs. controls

Author	Publication year	Country	IBD (HP+)	IBD (HP-)	CD (HP+)	CD (HP-)	UC (HP+)	UC (HP-)	Control (HP+)	Control (HP-)
Meining <sup>10</sup>	1997	Germany	3	33	3	33	-	-	13	23
Oberhube <sup>12</sup>	1997	Germany	25	50	25	50	-	-	78	115
D’Inca <sup>4</sup>	1998	Italy	31	77	19	58	12	29	17	26
Parlak <sup>13</sup>	2001	Turkey	74	37	28	17	46	20	49	28
Piodi <sup>14</sup>	2003	Italy	34	38	17	15	17	23	44	28
Pronai <sup>15</sup>	2004	Italy	17	116	7	44	10	72	78	122
Ando <sup>1</sup>	2008	Japan	3	35	3	35	-	-	5	7
Song <sup>19</sup>	2009	Korea	80	236	26	121	54	115	166	150
Zhang <sup>22</sup>	2011	China	57	311	27	165	30	146	208	288
Bartels <sup>2</sup>	2016	Denmark	71	424	8	116	63	308	10902	44558
Moriyama <sup>11</sup>	2005	Japan	3	26	3	26	-	-	5	2
Sonnenberg <sup>20</sup>	2018	USA	233	3477	72	1443	161	2034	23418	197404
Cho <sup>3</sup>	2018	Korea	56	133	25	66	31	67	281	350

IBD: inflammatory bowel disease; CD: Crohn's disease; UC: ulcerative colitis; HP: *Helicobacter pylori*

Table 2: Deterioration of IBD after *H. pylori* eradication or not

Author	Publication	Country	<i>H. pylori</i> eradication scheme	Eradication	No eradication	CDAI	CRP
Rosania <sup>16</sup>	2018	Germany	seven days triple therapy	4/14	18/55		
Shinzaki <sup>17</sup>	2018	Japan	seven days triple therapy	17/127	23/262	97±42 vs. 96±54	
Lahat <sup>6</sup>	2017	Israel	ten days sequential therapy	-	-	30.91 ± 25.2 vs.	5.12 ± 3.4 vs.
Lin <sup>7</sup>	2018	Taiwan	fourteen days therapy	666/20385	476/20575		
Mansour <sup>8</sup>	2018	Egypt	fourteen days triple therapy	-	-		12 ± 4.44 vs.

IBD: inflammatory bowel disease; CDAI: Crohn's disease activity index; CRP: C-reactive protein

Table 3: *H. pylori* infection occurring in different IBD classification

Author	Publication year	Country	Diagnosis	Mild (HP+/-)	Moderate or Severe (HP+/-)
Caner <sup>23</sup>	2014	Turkey	UC	19/14	9/7
Jin <sup>5</sup>	2013	China	UC	14/23	32/64
Xiang <sup>21</sup>	2013	China	CD	11/21	51/146
So <sup>18</sup>	2016	Korea	CD	3/23	7/13

IBD: inflammatory bowel disease

CD: Crohn's disease

UC: ulcerative colitis

HP: *Helicobacter pylori*

Table 4: H. pylori infection occurring in different IBD medication

Author	Publication year	Country	Sulfasalazine or mesalazine ( HP+/- )	corticosteroid or immunosuppressant ( HP+/- )
Oberhube <sup>12</sup>	1997	Germany	8/3	5/19
D’Inca <sup>4</sup>	1998	Italy	30/60	4/23
Song <sup>19</sup>	2009	Korea	76/244	41/153
Matsumura <sup>9</sup>	2011	Japan	9/33	8/30
Caner <sup>23</sup>	2014	Turkey	24/14	4/7

IBD: inflammatory bowel disease

HP: *Helicobacter pylori*

Reference:

1. Ando T, Watanabe O, Ishiguro K, Maeda O, Ishikawa D, Minami M, et al. Relationships between helicobacter pylori infection status, endoscopic, histopathological findings, and cytokine production in the duodenum of crohn's disease patients. *J Gastroenterol Hepatol* 2008;23 Suppl 2:S193-7. doi: 10.1111/j.1440-1746.2008.05438.x.
2. Bartels LE, Jepsen P, Christensen LA, Gerdes LU, Vilstrup H, Dahlerup JF. Diagnosis of helicobacter pylori infection is associated with lower prevalence and subsequent incidence of crohn's disease. *J Crohns Colitis*. 2016;10(4):443-8. doi: 10.1093/ecco-jcc/jjv229.
3. Cho JH, Lee DH, Shin CM. The prevalence of helicobacter pylori infection and inflammatory bowel disease: A single-center experience. *Journal of Gastroenterology and Hepatology* 2018;33:353.
4. D'Inca R, Sturniolo G, Cassaro M, di Pace C, Longo G, Callegari I, et al. Prevalence of upper gastrointestinal lesions and helicobacter pylori infection in crohn's disease. *Dig Dis Sci*. 1998;43(5):988-92. doi: 10.1023/a:1018870415898.
5. Jin X, Chen YP, Chen SH, Xiang Z. Association between helicobacter pylori infection and ulcerative colitis--a case control study from china. *Int J Med Sci*. 2013;10(11):1479-84. doi: 10.7150/ijms.6934.
6. Lahat A, Kopylov U, Neuman S, Levhar N, Yablecovitch D, Avidan B, et al. Helicobacter pylori prevalence and clinical significance in patients with quiescent crohn's disease. *BMC Gastroenterol*. 2017;17(1):27. doi: 10.1186/s12876-017-0588-7.
7. Lin KD, Chiu GF, Waljee AK, Owyang SY, El-Zaatari M, Bishu S, et al. Effects of anti-helicobacter pylori therapy on incidence of autoimmune diseases, including inflammatory bowel diseases. *Clin Gastroenterol Hepatol*. 2019;17(10):1991-1999. doi: 10.1016/j.cgh.2018.12.014..
8. Mansour L, El-Kalla F, Kobtan A, Abd-Elsalam S, Mousef M, Soliman S, et al. Helicobacter pylori may be an initiating factor in newly diagnosed ulcerative colitis patients: A pilot study. *World J Clin Cases*. 2018;6(13):641-649. doi: 10.12998/wjcc.v6.i13.641.
9. Matsumura M, Matsui T, Hatakeyama S, Matake H, Uno H, Sakurai T, et al. Prevalence of helicobacter pylori infection and correlation between severity of upper gastrointestinal lesions and h. Pylori infection in japanese patients with crohn's disease. *J Gastroenterol*. 2001;36(11):740-7. doi: 10.1007/s005350170015.
10. Meining A, Bayerdorffer E, Bastlein E, Raudis N, Thiede C, Cyrus B, et al. Focal inflammatory infiltrations in gastric biopsy specimens are suggestive of crohn's disease. Crohn's disease study group, germany. *Scand J Gastroenterol*. 1997;32(8):813-8. doi: 10.3109/00365529708996539.
11. Moriyama T, Matsumoto T, Jo Y, Yada S, Hirahashi M, Yao T, et al. Mucosal proinflammatory cytokine and chemokine expression of gastroduodenal lesions in crohn's disease. *Aliment Pharmacol Ther*. 2005;21 Suppl 2:85-91. doi: 10.1111/j.1365-2036.2005.02480.x.
12. Oberhuber G, Puspok A, Oesterreicher C, Novacek G, Zauner C, Burghuber M, et al. Focally enhanced gastritis: A frequent type of gastritis in patients with crohn's disease. *Gastroenterology*. 1997;112(3):698-706. doi: 10.1053/gast.1997.v112.pm9041230.
13. Parlak E, Ulker A, Disibeyaz S, Alkim C, Dagli U. There is no significant increase in the incidence of helicobacter pylori infection in patients with inflammatory

bowel disease in turkey. *J Clin Gastroenterol.* 2001;33(1):87-8. doi: 10.1097/00004836-200107000-00025.

14. Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M, et al. Possible protective effect of 5-aminosalicylic acid on helicobacter pylori infection in patients with inflammatory bowel disease. *J Clin Gastroenterol.* 2003;36(1):22-5. doi: 10.1097/00004836-200301000-00008.

15. Pronai L, Schandl L, Orosz Z, Magyar P, Tulassay Z. Lower prevalence of helicobacter pylori infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease - antibiotic use in the history does not play a significant role. *Helicobacter.* 2004;9(3):278-83. doi: 10.1111/j.1083-4389.2004.00223.x.

16. Rosania R, Von Arnim U, Link A, Rajilic-Stojanovic M, Franck C, Canbay A, et al. Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study. *J Gastrointest Liver Dis.* 2018;27(2):119-125. doi: 10.15403/jgld.2014.1121.272.hpy.

17. Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, et al. Seven days triple therapy for eradication of helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. *Intest Res.* 2018;16(4):609-618. doi: 10.5217/ir.2018.00044.

18. So H, Ye BD, Park YS, Kim J, Kim JS, Moon W, et al. Gastric lesions in patients with crohn's disease in korea: A multicenter study. *Intest Res.* 2016;14(1):60-8. doi: 10.5217/ir.2016.14.1.60.

19. Song MJ, Park DI, Hwang SJ, Kim ER, Kim YH, Jang BI, et al. [the prevalence of helicobacter pylori infection in korean patients with inflammatory bowel disease, a multicenter study]. *Korean J Gastroenterol.* 2009;53(6):341-7. doi: 10.4166/kjg.2009.53.6.341.

20. Sonnenberg A, Turner KO, Genta RM. Decreased risk for microscopic colitis and inflammatory bowel disease among patients with reflux disease. *Colorectal Dis.* 2018;20(9):813-820. doi: 10.1111/codi.14114.

21. Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, et al. Helicobacter pylori and crohn's disease: A retrospective single-center study from china. *World J Gastroenterol.* 2013; 28;19(28):4576-81. doi: 10.3748/wjg.v19.i28.4576.

22. Zhang S, Zhong B, Chao K, Xiao Y, Cui Y, Gao X, et al. Role of helicobacter species in chinese patients with inflammatory bowel disease. *J Clin Microbiol.* 2011;49(5):1987-9. doi: 10.1128/JCM.02630-10.

23. Caner S, Altinbas A, Yesil Y, Beyazit Y, Yilmaz B, Yüksel O, et al. The relation between helicobacter pylori and ulcerative colitis. *Turk J Med Sci.* 2014;44(5):820-3. doi: 10.3906/sag-1305-39.